Novo Nordisk has announced new clinical data from the positive phase 2 trial of investigational zenagamtide, also known as amycretin. Zenagamtide is the first of its class, being a unimolecular peptide agonist of GLP-1 and amylin receptors.

Presented at the 2026 Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, LA, results from the phase 2 dose finding study included the evaluation of 6 subcutaneous doses of zenagamtide (ranging from 0.4 mg to 40 mg) versus matched placebo in 262 adults with T2D inadequately controlled (A1C 7-10 percent) on metformin, with or without an SGLT2 inhibitor. The study met its primary endpoint of change in A1C across all doses and also key supportive secondary endpoint of change in body weight (with doses 1.5 mg and greater) with zenagamtide versus placebo after 36 weeks.

This trial used a fixed-dose-escalation trial design; if the planned treatment dose was not tolerated, treatment was permanently discontinued.

In the trial, the most common adverse events were gastrointestinal, and the majority were mild to moderate in severity. The safety and tolerability profile in this phase 2b trial was consistent with other incretin and amylin-based therapies. These results support further investigation of zenagamtide in phase 3 trials.

Based on the results, Novo Nordisk is planning to initiate a phase 3 development program with zenagamtide for adults with type 2 diabetes in H2 2026.

Martin Holst Lange, Chief Scientific Officer (CSO) and Executive Vice President (EVP)—Research and Development, Novo Nordisk, said, “Zenagamtide is the first investigational treatment for Type 2 Diabetes to combine GLP-1 and amylin receptor agonist mechanisms of action in a single molecule. These phase 2 results build on the growing body of evidence which demonstrates the potential of zenagamtide to meaningfully impact blood glucose control in patients with Type 2 Diabetes and also body weight. These results underscore our scientific leadership and position us to continue advancing innovative treatment options that could expand the therapeutic landscape and provide patients and healthcare professionals with greater choice in managing Type 2 Diabetes."